Stem Cells Spin Income Statement

Financials in millions PLN. Fiscal year is January - December.

Millions PLN. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	0.07	0.05	0.42	0.25	0.53
Revenue Growth (YoY)	21.11%	-87.06%	68.84%	-52.78%	96.00%
Cost of Revenue	0.02	0.01	0.04	0.02	0.02
Gross Profit	0.05	0.05	0.37	0.23	0.5
Selling, General & Admin	0.1	0.11	0.12	0.11	0.29
Other Operating Expenses	-1.07	-1.05	-0.68	-0.62	-0.57
Operating Expenses	0.57	0.56	0.53	0.44	0.58
Operating Income	-0.52	-0.52	-0.15	-0.21	-0.08
Interest Expense	-	-0	-0	-0	-0.04
Other Non Operating Income (Expenses)	-0	-	-0	-0	-0.01
EBT Excluding Unusual Items	-0.52	-0.52	-0.15	-0.21	-0.12
Gain (Loss) on Sale of Assets	-	-	-	0.24	-0
Pretax Income	-0.52	-0.52	-0.15	0.03	-0.13
Net Income	-0.52	-0.52	-0.15	0.03	-0.13
Net Income to Common	-0.52	-0.52	-0.15	0.03	-0.13
Shares Outstanding (Basic)	41	41	41	41	41
Shares Outstanding (Diluted)	41	41	41	41	41
EPS (Basic)	-0.01	-0.01	-0.00	0.00	-0.00
EPS (Diluted)	-0.01	-0.01	-0.00	0.00	-0.00
Free Cash Flow	-0.09	0.04	0.09	-0.6	0.66
Free Cash Flow Per Share	-0.00	0.00	0.00	-0.01	0.02
Gross Margin	75.05%	86.17%	89.36%	91.75%	95.49%
Operating Margin	-787.13%	-951.51%	-35.88%	-84.14%	-14.61%
Profit Margin	-787.98%	-958.49%	-36.81%	10.71%	-24.23%
Free Cash Flow Margin	-130.71%	79.99%	22.35%	-240.95%	125.26%
EBITDA	1.01	0.98	0.93	0.75	0.77
EBITDA Margin	1536.55%	1807.98%	222.94%	300.13%	147.33%
D&A For EBITDA	1.53	1.5	1.09	0.95	0.85
EBIT	-0.52	-0.52	-0.15	-0.21	-0.08
EBIT Margin	-	-	-35.88%	-84.14%	-14.61%
Revenue as Reported	0.07	0.05	0.39	0.25	0.53

Source: S&P Global Market Intelligence. Standard template. Financial Sources.